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ABSTRACT 
There are very few reports on the epidemiology of chronic hypoparathyroidism. A population-
based study was undertaken to describe the prevalence and incidence of hypoparathyroidism 
in Tayside, Scotland. Data on biochemistry, hospital admissions, prescribing and death records 
in Tayside Scotland from 1988 to 2015 were linked electronically. Patients with at least three 
serum albumin corrected calcium concentrations below the reference range that were taken in 
an out-patient setting were included in the study.  Patients with severe chronic kidney disease 
prior to low calcium were excluded from the study.  Patients with hypocalcaemia were included 
if they had either previous neck surgery/irradiation, a low serum PTH or were treated with 
Vitamin D. Patients were identified as having either a post-surgical, a non-surgical cause, or 
had secondary hypoparathyroidism e.g. hypomagnesaemia. Overall 18,955 patients were 
identified with hypocalcaemia.  Of these 222 patients had primary hypoparathyroidism, 116 
with post-surgical and 106 with non-surgical chronic hypoparathyroidism. In 2015 the 
prevalence of primary hypoparathyroidism was 40 per 100,000, with a rate of 23 and 17 per 
100,000 respectively for post-surgical and non-surgical.  80% of the former and 64% of the 
latter were female.  The mean serum calcium at diagnosis was 1.82mmol/l (SD ± 0.24) and the 
annual incidence varied from 1-4 per 100,000.  Overall, 71% of patients were prescribed 
Vitamin D and/or calcium, whilst activated Vitamin D was used in 48% of post-surgical cases 
and 43% of non-surgical cases. Thyroxine and/or hydrocortisone were prescribed in over 90% 
of post-surgical and 64% of non-surgical cases. In conclusion, the prevalence of non-surgical 
chronic hypoparathyroidism was greater than previously reported using this population-based 
approach.  Many had mild hypocalcaemia and did not receive any treatment. This article is 
protected by copyright. All rights reserved   
Key words: General population study, epidemiology, Parathyroid-related disorders, Health 
Services Research, Statistical Methods 
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INTRODUCTION 
Hypoparathyroidism is a rare condition that may present with a range of symptoms from having 
no symptoms to life threatening hypocalcaemia (1,2).  Symptoms are broadly related to the 
severity of hypocalcaemia.  Hypoparathyroidism may be transient, such as after neck surgery, 
or may be chronic.  Chronic hypoparathyroidism can result from permanent damage to the 
parathyroid glands from surgery or radiotherapy and is closely related to the number of 
parathyroid glands remaining after surgery (3).  Autoimmunity and rare genetic conditions may 
also cause hypoparathyroidism, but many cases remain idiopathic (4).  Hypoparathyroidism 
can be due to other correctable causes including hypomagnesaemia, which can be treated with 
magnesium replacement.  Not all patients require treatment, such as those with mild 
hypocalcaemia.  For those who do require therapy, this is usually in the form of activated 
vitamin D analogues, such as 1-alpha calcidol or calcitriol, with or without calcium tablets.  
Traditionally, the aim of treatment has been to maintain the serum calcium level around the 
lower limit of the reference range, to limit the risks of hypercalciuria and hypercalcaemia with 
the resultant risks of symptoms, renal stones, and other complications.  Treatment may become 
more straightforward with the introduction of parathyroid hormone as a substitute therapy.  
Post-surgical hypoparathyroidism is the commonest cause of hypoparathyroidism, occurring 
in 25 - 60% of surgical neck explorations (4-6).  However, the majority are transient cases, 
with 70% resolving after 2 months, 90% at 6 months and possibly as few as 2-5% persist at 
one year (5,7). In Denmark, the prevalence of hypoparathyroidism was studied using the 
national hospital contact disease register linked to prescribing records (8,9).  The overall 
prevalence was around 24 per 100,000 people, with rates of 22 per 100,000 chronic post 
surgical cases (9) and 2.3 per 100,000 non-surgical cases (8).  There was a female 
predominance of around 88% in post-surgical hypoparathyroidism (9), but only 53% in non-
surgical cases (9).   The average age was 49 and 50 years respectively.  The annual incidence 
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of cases was around 0.8 per 100,000 people (9), with an incidence of about 0.1 per 100,000 of 
autoimmune hypoparathyroidism (10).  Interestingly around 4% of people were treated with 
magnesium (9).   
Another study in Norway using hospital registry reported that the prevalence of 
hypoparathyroidism was lower at 10.2 per 100,000 (11), but this reflected a lower proportion 
of post-surgical cases at 6.4 per 100,000, and a higher rate of non-surgical cases of 3.0 per 
100,000.  An estimated prevalence of hypoparathyroidism of around 37 per 100,000 in the US 
has been reported in an abstract (12,13), with a rate of 8 per 100,000 non-surgical cases.  From 
a further US study based on a health care claims database and a market-based research study, 
an approximate prevalence of 25 cases per 100,000 was estimated (5).    Further studies have 
demonstrated a prevalence of hospitalisations due to hypoparathyroidism of 5.9 per 100,000 
(14) and idiopathic hypoparathyroidism of 0.7 to 0.9 per 100,000 (15,16).  The latter two 
studies were pre-2000 and it is difficult to know if rates have increased or whether 
ascertainment has improved. 
Most of these studies rely on hospital based records with prescribing data in a proportion of 
studies.  As primary care records were not included it is possible some cases may have been 
missed, especially milder non-surgical related cases that may not even have needed treatment.  
We were able to link hospital records with primary care information, prescribing and 
biochemistry records to identify cases with chronic hypoparathyroidism.  We aimed to describe 
the epidemiology of chronic hypoparathyroidism using this population-based dataset in 
Tayside, Scotland. 
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METHODS  
Patients 
All patients registered with a General Practitioner in Tayside are issued with a unique ten digit 
patient identification code which has been used for all healthcare activity since 1979. All such 
records are held at the Health Informatics Centre and linked anonymously for healthcare 
research (HIC, http://www.dundee.ac.uk/hic) at the University of Dundee. The study was 
approved by the Tayside Medical Ethics Committee and data protection by the Tayside 
Caldicott Guardians. All analyses were performed on anonymised datasets.  The following 
datasets were linked: biochemistry, hospital admission (Scottish Morbidity Records (SMR)), 
drug prescribing records, death and patient migration (General Registry Office). 
 
a) Primary analysis 
All patients of 18 years and over who had a low serum calcium concentration recorded on at 
least three occasions more than one month apart (<= 2.15mmol/L) were identified from the 
biochemistry dataset in Tayside.  All serum calcium concentrations mentioned in this study 
were corrected for albumin concentration. Only recordings undertaken as outpatients were 
included in this study because many inpatients have transient hypocalcaemia.  Patients who in 
addition also had at least one of the following criteria were classified as potentially having 
hypoparathyroidism: 
1. Evidence of previous neck surgery or irradiation prior to hypocalcaemia or admission 
with hypoparathyroidism.  Data was collected from SMR and operation procedures.  
a. OPCS codes: B08, B09, B12, B14, E29.8, E29.9, E30, E31, E34, E35, E38 
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b. ICD10 codes: D02.0, C32.0, C32.1, C32.2, C32.3, C32.8, C32.9, C73, Z85.21, 
Z85.850  
c. ICD9 codes: 231.0, 161.0, 161.1, 161.2, 161.3, 161.8, 161.9, 193, v10.21, 
v10.87 
d.  ICD 9/10 codes for hypoparathyroidism: 252.1, E20.8, E20.9, E82.1 and E89.2. 
2. Low or inappropriately normal plasma parathyroid hormone (PTH) while having low 
calcium (within 4 months) – PTH <=5pmol/L or 50ng/L (reference range 1-6.9 
pmol/L).  Data was collected from Biochemistry. 
3. On long term treatment with Calcium (BNF code: 9.5.1.1) and/or any Vitamin D (BNF 
code: 9.6.4) drugs – at least 3 prescriptions in a year.  Data was collected from 
prescribing dataset. 
Patients were excluded based on the following criteria (see Figure 1): 
1. Patients who had high serum PTH (>7pmol/L) while having low calcium (within 4 
months), as this represents secondary hyperparathyroidism and not primary 
hypoparathyroidism. 
2. Patients who had low Vitamin D while having low calcium (within 4 months) in the 
absence of a low serum PTH, as this was most likely to represent secondary 
hyperparathyroidism and not primary hypoparathyroidism. 
3. Patients who had less than three low calcium levels after excluding calcium 
measurements taken during admission.  Patients with hypocalcaemia whilst being in 
the hospital may be due to malnutrition and critical illness and is thus unrelated to 
chronic parathyroid disease.   
4. Patients who had low calcium concentrations as an outpatient, but all within 1 month 
of each other, as this did not represent sustained hypocalcaemia and was likely to be 
transient disease. 
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5. Use of bisphosphonates and denosumab (BNF code: 6.6.2) within 6 months prior to 
low calcium measurement.  
 
Therefore, patients would have had at least three low serum calcium concentrations undertaken 
as an outpatient at least one month apart were included in this study.  These criteria are likely 
to exclude all patients with transient hypocalcaemia, but in addition the percentage of patients 
with a low serum calcium concentration recorded more than 3 and 6 months apart was 
measured.   
Patients who met all the criteria above were then categorised into three groups to help to 
confirm the cause of hypoparathyroidism based on the criteria below (see figure 1): 
1. Evidence of previous neck surgery or irradiation prior to hypocalcaemia  
2. Low magnesium levels within 3 months of having low calcium.  
3. Uncategorised with a normal serum magnesium concentration (or no record of serum 
magnesium) within 3 months of having low calcium.  
 
b) Secondary Analysis 
Based on the primary analysis, the patients in the uncategorised group were defined as having 
‘non-surgical hypoparathyroidism’ if they met any of the following criteria. The rest of the 
uncategorised patients were excluded from the cohort (see Figure 1). 
1. Patients who always had PTH <= 5pmol/L, at least one within 4 months of low serum 
calcium and were on alfacalcidol or calcitriol, or had an inpatient admission recorded 
as hypoparathyroidism 
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2. Patients who always had PTH <= 5pmol/L within 4 months of having low serum 
calcium but were not on alfacalcidol or calcitriol 
3. Patients who did not have any PTH recording during the study period but were on 
alfacalcidol/calcitriol  
4. Patients who did not have any PTH recording during the study period, were not on 
activated Vitamin D but were on hydrocortisone or/and thyroxine 
Finally patients who had an eGFR <20 or creatinine > 200µmol/L prior or on the day of the 
first low serum calcium were excluded from the study (all subgroups).  These patients are most 
likely to be hypocalcaemic and on activated Vitamin D as a result of chronic kidney disease as 
the renal failure predated the hypocalcaemia.  The main reason other patients were excluded 
was because they had no serum PTH assay, were not on activated Vitamin D, hydrocortisone 
nor thyroxine  
 
c) Prevalence and incidence rates 
The yearly and 5 yearly prevalence and incidence rates were calculated for the whole cohort 
that included those with post-surgical hypoparathyroidism, non-surgical hypoparathyroidism 
and hypoparathyroidism secondary to hypomagnesaemia.  Estimates were also calculated for 
post-surgical and non-surgical groups separately.  
 
RESULTS: 
After applying the inclusion and exclusion criteria, a total of 280 patients were identified 
(Figure 1). There were 116 patients in the post-surgical cohort, 106 patients in the idiopathic 
non-post-surgical cohort and 58 with secondary hypoparathyroidism due to hypomagnesaemia.  
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The median duration of follow up was 107 months for all patients and 116 months for patients 
with post-surgical or non-surgical primary hypoparathyroidism.  Classification of patients from 
the idiopathic non-surgical group into four subgroups is illustrated in Figure 2. The baseline 
characteristics of these patients are illustrated in Tables 1 and 2. Patients with 
hypomagnesaemia were older and less likely to be treated with activated Vitamin D 
preparations compared to patients in the post-surgical and idiopathic non-surgical groups  
Of all patients in our cohort, 88.2% (n=247) had low serum calcium measurements more than 
3 months apart and 79.3% (n=222) had them more than 6 months apart.  This figure increases 
to 83% for a 6 months duration if all serum calcium recordings are included i.e. in-patient and 
out-patient. In the non-surgical group, 85% of the patients had hypocalcaemia for 6 months or 
longer. Overall 59.1% of patients with hypoparathyroidism had a serum PTH checked.  
The post-surgical group had a higher proportion of females, and a lower nadir plasma PTH 
concentration than the idiopathic non-surgical cases (Table 1).  Within the latter group, those 
not treated with activated Vitamin D had higher nadir serum calcium and PTH concentrations, 
suggestive of milder disease, than other non-surgical hypoparathyroid cases (Table 2).  A large 
proportion of the non-surgical cases (64%) and the hypomagnesaemia cases (69%) were on 
hydrocortisone and/or thyroxine, suggestive of a possible ongoing autoimmune process. 
Severity of disease was assessed by measuring the lowest ever concentration of serum calcium 
for the post-surgical and non-surgical patients.  For post-surgical and non-surgical cases 
respectively, the proportion of patients with the lowest recorded serum calcium below 2.1 mol/l 
were 93.1% and 95.3%, serum calcium below 2.0mmol/l were 75.9% and 59.4% and a serum 
calcium below 1.8 mmol/l were 44.8% and 31.1%.  For patients treated with activated Vitamin 
D (n=118) the proportion who subsequently developed a serum calcium <1.85 mmol/l was 
6.8%, who developed a serum calcium >2.55mmol/l was 1.7% and who developed a serum 
phosphate >1.5 mmol/l was 22.0%.   
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The prevalence and incidence rates for the whole cohort, post-surgical and idiopathic non-
surgical is illustrated in yearly and 5-yearly bands in Tables 3 and 4. In 2015, the prevalence 
rate for the whole cohort was 47 per 100,000 people and 40 per 100,000 for the combined 
endpoint of post-surgical (23 per 100,000) and non-surgical patients (17 per 100,000).  
As a sensitivity analysis we re-calculated the prevalence for 2015 after excluding all patients 
who a) had low serum calcium concentrations less than 6 months or b) had a low serum albumin 
concentration and a serum PTH >1.6 pmol/L.  It could be argued that the latter group had 
malabsorption as their cause for hypocalcaemia.  After excluding these groups the overall 
prevalence for the combined endpoint of post-surgical and non-surgical hypoparathyroidism 
was 32 per 100,000 with rates of post-surgical and non-surgical hypoparathyroidism being 18 
and 14 per 100,000 respectively.  
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DISCUSSION 
We estimated the prevalence of endogenous chronic hypoparathyroidism in 2015 to be 40 per 
100,000 which is similar to the rate observed in the US at 37 per 100,000 (12) but greater than 
that seen in other European studies at 10-24 per 100,000 (8, 9, 11).  Our prevalence of 23 per 
100,000 of the population for post surgical hypoparathyroidism is broadly similar to most other 
estimates from Europe, and the US at 22 to 29 per 100,000 (9,12,13).   
Our prevalence of 17 per 100,000 for non-surgical hypoparathyroidism however is 
significantly greater than previous estimates of non-surgical hypoparathyroidism, where rates 
of around 2-3 per 100,000 in Denmark, and Norway (8,11) have been reported.  In the US 
study, the non-surgical prevalence was 8 per 100,000 (12,13).  In our non-surgical cohort, only 
71% of patients were on calcium or Vitamin D, indicating that a number of patients had mild 
hypocalcaemia not noticed or not deemed to require calcium replacement.  Two thirds of 
patients in the non-surgical group were on hydrocortisone and/or thyroxine suggestive of a 
history of autoimmunity, a common cause of non-surgical hypoparathyroidism. This is an 
indicative that many patients had an autoimmune condition, increasing the likelihood of 
hypoparathyroidism.  Unfortunately we did not have access to immunology data for auto-
antibody results. There will be a number of reasons why only 59% of patients had a recording 
of plasma PTH.  Many of these patients may not have had a formal diagnosis of 
hypoparathyroidism, with results being missed, ignored or judged as irrelevant and not needing 
treatment by clinicians.  Such patients may not have been referred for specialist opinions – 
especially in non-surgical cases.  There may also have been problems with data-linkage or lack 
of availability of PTH assays before they became widely available (e.g. in the 1980s).   
When patients with hypocalcaemia for less than 6 months and those in whom it could be argued 
may have malabsorption (low albumin, low calcium and inappropriately normal PTH) were 
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excluded, the rate of hypoparathyroidism fell from 40 to 32 per 100,000 with rates of 18 and 
14 per 100,000 in the post-surgical and non-surgical groups respectively.  This still indicates a 
post-surgical prevalence similar to the literature but the non-surgical prevalence remains 
significantly greater than previously reported.   
The higher proportion of non-surgical patients identified in our study may be due to the method 
used. In this study patients were identified using biochemistry records in primary and 
secondary care, which were linked and augmented by hospital registrations and prescribing 
records.  Previous studies have been mainly based on patient registrations and/or prescribing.   
It is likely that most post-surgical cases would have been seen and registered in a hospital 
clinic, as reflected by the similar prevalence between the current study and previous ones.  
However, it is to be expected that our methodology would identify patients who were not 
identified in previous studies.  Our methodology would identify patients that fit the criteria for 
hypoparathyroidism but have not previously been recognised and/ or not been referred to a 
specialist and/or not placed on a register or inappropriately removed from a database.  It is 
likely that the additional patients that we identified would have less severe disease that did not 
necessitate hospital care, or even drug treatment. All our patients had three serum calcium 
concentrations below 2.15 mmol/L in an out-patient setting and 94% had a serum calcium less 
than 2.10 mmol/L.  Thus, a small number of patients (~6%) had marginal hypocalcaemia which 
may not have been of clinical significance.   In some other cohorts, it seems that virtually all 
patients were on activated Vitamin D (11), whilst 25% of our overall cohort did not require 
regular calcium and/or Vitamin D treatment, again suggesting milder disease in our cohort.  
Although some of the patients we identified had mild biochemical abnormalities, we cannot 
comment on the severity of their symptoms or quality of life.  
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In our analysis, approximately 60% of people with non-surgical hypoparathyroidism were 
likely to have had autoimmune disease, as judged by co-prescribing of thyroxine and/or 
hydrocortisone, which is higher than the 17% reported by Astor (11).  Unfortunately, we did 
not have robust data on genetic causes, but previous studies have estimated genetic causes to 
be 31-38% of all non-surgical (living) cases (15, 16), with the commonest being CASR gene 
mutations, Di-George syndrome and HDR syndrome (hypoparathyroidism, deafness and renal 
abnormalities).  If this figure were applicable to our population this would leave approximately 
10% as genuinely idiopathic.   
The annual incidence of non-surgical hypoparathyroidism was generally around 1-4 per 
100,000 of the general population but did vary quite considerably from year to year.  The rate 
is higher than the only other reported incidence we could identify from Denmark of 0.8 per 
100,000 (9).  Although this may reflect methodological differences explained above there are 
very few studies reporting the incidence of hypoparathyroidism. 
There are a number of possible reasons for regional variation in the rates of 
hypoparathyroidism.  Post-surgical hypoparathyroidism will reflect the amount of thyroid 
surgery being undertaken, which will partly reflect different and changing practices in the use 
of radioactive iodine for benign thyroid disease.  Locally, surgery for benign thyroid disease 
has decreased (17) and this may explain the declining post-surgical incidence of 
hypoparathyroidism.  Also the rates of chronic post-surgical hypoparathyroidism between 
centres appear to vary significantly possibly from 1 to 15% (18).  Non-surgical 
hypoparathyroidism has a strong genetic aetiology, and it is likely that there will be “pockets” 
of disease reflecting clusters of genetic abnormalities.  It is also known that autoimmune 
diseases have geographical clustering, all of which will affect the prevalence of 
hypoparathyroidism.  
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Further analysis of the subgroups of idiopathic non-surgical hypoparathyroidism (Figure 2) is 
of interest.  It should be remembered that all these patients had chronic hypocalcaemia from 
samples taken when not in hospital.  Group 1 had very strong criteria that match a diagnosis of 
hypoparathyroidism – as they had a low or inappropriately normal PTH concentration and were 
on activated Vitamin D, or had an ICD code for hypoparathyroidism.  Group 2 are highly likely 
to have hypoparathyroidism, but it is likely that many had longstanding disease dating back to 
a time when PTH assays were less easily accessed and less reliably recorded.  These patients 
had chronic hypocalcaemia and were on activated Vitamin D and did not have renal failure at 
baseline.  Group 2 and 4 both had very high rates of co-prescribing thyroxine and/or 
hydrocortisone consistent with previous neck surgery or having a poly-endocrinopathy.  Even 
in group 3 where patients fitted the biochemical criteria for diagnosis but were not taking 
activated Vitamin D, 50% were co-prescribed thyroxine and/or hydrocortisone.  As discussed 
it is likely that many of this group had mild hypocalcaemia as reflected by a higher nadir serum 
calcium and a lower prescribing rate for calcium replacement therapies (Table 2).  These 
however are the type of patient who are easily missed in epidemiological studies.   
The strength of our study is that it is population-based and will include review of anyone who 
has had contact with a healthcare professional in primary and secondary care. We used an 
algorithm which will have identified patients missed by other studies but it is possible that we 
may have misclassified some patients with transient disease as having chronic 
hypoparathyroidism.  We tried to limit this by only including serum calcium collections 
undertaken more than 4 weeks apart and taken as an outpatient, as most transient 
hypocalcaemia occurs in inpatients.  In addition, 88% of patients had low serum calcium 
measurements more than 3 months apart and 83% more than 6 months apart by which time 
many patients would have been established on replacement treatment.   We may have failed to 
identify some cases as post-surgical if there were coding inaccuracies. However our overall 
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post-surgical prevalence rate is similar to other reports and therefore the high rate of non-
surgical cases we identified is more likely to be genuine and reflect the population-based 
methodology.  We have not included patients with pseudohypoparathyroidism.  It is likely that 
our calculated prevalence of hypoparathyroidism is an underestimate as we were quite stringent 
about excluding cases in whom we were not confident about the diagnosis, and some cases 
may have been missed using our methodology. When patients were identified using only ICD 
codes for hypoparathyroidism, only three patients (~1%) who would not have been identified 
from other combined sources using the algorithm were identified. This suggest the algorithm 
used to identify patients was fairly robust. It is possible that we over-diagnosed some cases on 
non-surgical hypoparathyroidism.  However a sensitivity analysis which removed cases with 
low calcium less than 6 months or people with possible malabsorption as a cause of the 
hypocalcaemia indicated a prevalence rate of non-surgical hypoparathyroidism that remained 
well above the reported literature.  It would have been ideal if we could have looked at the 
causes of the non-surgical cases in more detail, and identify genetic, autoimmune and 
infiltrative causes, but the data was insufficient to allow such a detailed analysis.  Serum 
calcium concentrations were always corrected for albumin concentration in this study.  
Although estimations of ionised calcium concentrations would have been preferable, this is not 
done as part of routine practice in most UK Laboratories.  
In summary, the current study describes the epidemiology of chronic hypoparathyroidism using 
a different methodology to that used in the published literature, which is population-based.  The 
rate of post-surgical hypoparathyroidism was 23 per 100,000 which is similar to previous 
reports, but the prevalence of non-surgical hypoparathyroidism was 17 per 100,000 which is 
2-6-fold higher than reported before, although many of these patients had mild hypocalcaemia 
and some did not need activated Vitamin D treatment.   
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FIGURE LEGENDS: 
Figure 1: Pathway used to identify patients with hypoparathyroidism 
Figure 2: Classification of Idiopathic non-surgical cases 
 
Table 1: Baseline characteristics 
Variables Cohort Sub-cohort 
Post-
Surgical 
Non-
surgical 
Hypomagnesaemia 
N (%) 280 116 (41.4) 106 (37.9) 58 (20.7) 
Gender – Male, n (%) 86 (30.7) 23 (19.8) 38 (35.8) 25 (43.1) 
Age, mean (SD) 51.6 (19.3) 47.1 (19.9) 50.5 (17.9) 62.8 (16.1) 
Lowest Calcium, mean (SD) 1.82 (0.24) 1.83 (0.20) 1.88 (0.22) 1.70 (0.30) 
Lowest PTH, mean (SD) 1.80 (1.53) 1.12 (1.06) 2.19 (1.65) 1.85 (1.52) 
On Vitamin D or calcium (%) 212 (75.7) 82 (70.7) 75 (70.8) 55 (94.8) 
Alfacalcidol/calcitriol, n (%)  118 (42.1) 56 (48.3) 45 (42.5) 17 (29.3) 
Thyroxine/hydrocortisone, n (%) 213 (76.1) 105 (90.5) 68 (64.2) 40 (69.0) 
 
 
Table 2: Baseline characteristics – for the idiopathic non-surgical group 
Variable Group 1 Group 2 Group 3 Group 4 
N (%) 24 22 49 11 
Gender – Male, n (%) 9 (37.5) 8 (36.4) 16 (32.7) 5 (45.5) 
Age, mean (SD) 48.7 (20.2) 53 (16.5) 47.6 (17.2) 62 (14.9) 
Lowest Calcium, mean (SD) 1.62 (0.23) 1.87 (0.17) 1.97 (0.13) 2.03 (0.05) 
Lowest PTH, mean (SD) 0.79 (0.84) - 2.88 (1.51) - 
Alfacalcidol/calcitriol, n (%)  23 (95.8) 22 (100.0) - - 
Thyroxine/hydrocortisone, n (%) 15 (62.5) 17 (77.3) 25 (51.0) 11 (100.0) 
Group 1: Patients who always had PTH <= 5pmol/L and were on alfacalcidol or calcitriol and who were 
identified through ICD codes in the admission record 
Group 2: Patients who did not have any PTH recording but were on alfacalcidol or calcitriol 
Group 3: Patients who always had PTH <= 5pmol/L and had low or inappropriately normal PTH while 
having low calcium (within 4 months) but were not on alfacalcidol or calcitriol 
Group 4: Patients who did not have any PTH recording and were not on activated Vitamin D but were 
on hydrocortisone or/and thyroxine 
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Table 3: Yearly prevalence and incidence rate of hypoparathyroidism 
 
 
 
  
Year Prevalence rate (%) Incidence rate (per 100,000 population) 
Cohort Surgical 
cohort 
Idiopathic 
non-surgical 
cohort 
Cohort Surgical 
cohort 
Idiopathic non-
surgical cohort 
1988 0.002 0.000 0.002 1.802 0.000 1.802 
1989 0.005 0.001 0.004 3.609 0.773 2.578 
1990 0.008 0.001 0.006 2.307 0.513 1.282 
1991 0.011 0.003 0.007 3.833 1.789 1.533 
1992 0.016 0.004 0.009 4.313 1.269 1.522 
1993 0.019 0.006 0.010 3.793 2.276 1.264 
1994 0.023 0.008 0.011 5.051 2.020 1.515 
1995 0.028 0.009 0.013 5.790 1.259 3.273 
1996 0.029 0.010 0.013 0.758 0.253 0.253 
1997 0.028 0.009 0.013 0.253 0.000 0.253 
1998 0.027 0.009 0.013 0.508 0.254 0.254 
1999 0.027 0.010 0.012 1.019 0.509 0.255 
2000 0.027 0.010 0.012 0.512 0.512 0.000 
2001 0.028 0.011 0.012 2.058 1.543 0.257 
2002 0.029 0.012 0.012 1.288 1.030 0.258 
2003 0.031 0.014 0.012 2.573 1.544 0.257 
2004 0.032 0.015 0.012 1.794 1.025 0.000 
2005 0.032 0.015 0.012 0.763 0.254 0.509 
2006 0.033 0.016 0.012 1.771 1.012 0.253 
2007 0.034 0.017 0.012 1.757 1.255 0.502 
2008 0.036 0.018 0.013 2.986 0.995 1.493 
2009 0.039 0.020 0.013 4.204 2.226 0.989 
2010 0.040 0.020 0.013 2.948 1.474 0.491 
2011 0.043 0.021 0.015 3.413 1.463 1.463 
2012 0.047 0.023 0.017 4.857 1.214 2.429 
2013 0.049 0.024 0.017 3.154 1.456 1.213 
2014 0.048 0.024 0.017 2.175 0.725 0.483 
2015 0.047 0.023 0.017 0.723 0.482 0.241 
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Table 4: Prevalence and incidence of hypoparathyroidism – 5 year block    
 
 
 
 
  
Year Prevalence rate (%) Incidence rate (per 100,000 population) 
Cohort Surgical 
cohort 
Idiopathic non-
surgical cohort 
Cohort Surgical 
cohort 
Idiopathic non-
surgical cohort 
1990-1994 0.025 0.009 0.011 19.282 7.865 7.104 
1995-1999 0.031 0.010 0.014 8.347 2.277 4.300 
2000-2004 0.035 0.015 0.013 8.241 5.666 0.773 
2005-2009 0.042 0.020 0.015 11.547 5.773 3.765 
2010-2014 0.053 0.025 0.019 16.515 6.315 6.072 
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